Denali Therapeutics

About:

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Website: https://www.denalitherapeutics.com

Top Investors: F-Prime Capital, ARCH Venture Partners, Google Ventures, Alaska Permanent Fund, Eight Roads Ventures

Description:

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Total Funding Amount:

$1.12B

Headquarters Location:

San Francisco, California, United States

Founded Date:

2013-01-01

Founders:

Alexander Schuth, Marc Lavigne, Ryan Watts

Number of Employees:

251-500

Last Funding Date:

2024-02-27

IPO Status:

Public

© 2025 bioDAO.ai